Ordaos, a drug design company, was selected for the AWS Generative AI Accelerator.
The accelerator is a mentorship program for companies working with generative artificial intelligence. Ordaos was one of 21 companies selected for the program, according to a May 31 Ordaos news release.
The company will use the accelerator program to find biopharma partners.
"At Ordaos, we believe that the evolution of AI and machine learning will ultimately lead to nothing less than a true paradigm shift in how early drug design, no longer discovery, is done," Ordaos CEO David Longo said. Our mission at Ordaos is to define the design standard and we are excited to learn from other visionaries in the program to help advance our efforts."